Last updated: June 2, 2026
Buprenorphine Hydrochloride and Naloxone Hydrochloride Suppliers: API, Finished Dosage, and Contract Manufacturing
Executive summary: Suppliers for buprenorphine hydrochloride and naloxone hydrochloride span (1) API producers for each active, (2) contract manufacturers (CMOs) producing sublingual film/tablet combinations, and (3) finished-dose brand and generic holders distributing through wholesalers. The supplier set depends on whether the buyer needs APIs, combination finished product (e.g., sublingual film or tablet), or packaging/repack. The dominant manufacturing footprint in the US is concentrated around combination products used for opioid use disorder.
Who supplies buprenorphine hydrochloride and naloxone hydrochloride APIs for generic manufacturers?
Featured snippet answer: API supply for buprenorphine hydrochloride and naloxone hydrochloride comes from multiple global chemical and pharmaceutical intermediates producers, but most downstream generic and CMO customers qualify a narrow set under cGMP and DMF/CEP documentation requirements.
Buprenorphine hydrochloride API suppliers (common sources)
Buprenorphine hydrochloride API is produced by specialty pharma and fine-chemical manufacturers with cGMP lines and established regulatory files (US DMF and/or EU CEP). API supply is typically split by:
- Synthesis scale (commercial kilograms vs. specialty lots)
- Regulatory file readiness (DMF status, ASMF readiness, CEP updates)
- Salt form control (buprenorphine HCl consistency, crystallinity, polymorph control)
Naloxone hydrochloride API suppliers (common sources)
Naloxone hydrochloride API is supplied by opioid antagonist API producers with controlled impurity profiles aligned to combination product specifications.
API supply patterns for the combination
Combination products (buprenorphine/naloxone) typically source:
- Buprenorphine HCl API
- Naloxone HCl API
from qualified API vendors, then CMOs formulate into the target dosage (sublingual film, tablet).
Which contract manufacturers (CMOs) make buprenorphine/naloxone sublingual film and tablet?
Featured snippet answer: CMOs for buprenorphine/naloxone typically operate in sublingual solid dose manufacturing, with equipment and process validation tailored to content uniformity, low-dose uniformity, and moisture/handling controls for sublingual formats.
Sublingual film manufacturing capabilities
Buprenorphine/naloxone sublingual films require control of:
- Polymer matrix coating uniformity
- Solvent system and drying profile
- Micronization and blending strategy to manage dose uniformity
- Stability under temperature and humidity
Sublingual tablet manufacturing capabilities
Buprenorphine/naloxone sublingual tablets (and ODT-like configurations) require control of:
- Granulation and compression uniformity
- Disintegration profile
- Sublingual dissolution time targets
- Lubricant and binder selection for impurity and dissolution control
What suppliers deliver finished buprenorphine/naloxone combination products in the US?
Featured snippet answer: Finished product supply is driven by the brand and generic label holders distributing through US channels, with manufacturing executed by branded manufacturers and/or outsourced CMOs.
Brand and major generic supply structure
In the US, the supply chain for buprenorphine/naloxone combination products usually breaks down into:
- Marketing authorization holder (label owner)
- Manufacturer of record (often a CMO for generics or a branded site)
- Packaging site(s) for NDC-level distribution
How does supplier selection differ for APIs versus combination finished dosage?
Featured snippet answer: API sourcing focuses on regulatory file alignment and impurity specification control; finished-dose sourcing focuses on validated sublingual performance, stability, and regulatory equivalence (ANDA/505(b)(2)).
API procurement criteria
- DMF/ASMF availability for regulatory submission support
- Impurity and solvent residual specifications
- Polymorph and crystallinity control (buprenorphine HCl)
- Batch traceability and change control constraints
Finished-dose procurement criteria
- ANDA/label equivalence requirements (strength, route, dosage form)
- Film/tablet performance (dissolution/disintegration)
- Packaging configuration and NDC readiness
- Stability commitments for shelf life and storage conditions
What patent landscape affects sourcing and supplier switching for buprenorphine/naloxone?
Featured snippet answer: Patent coverage for buprenorphine/naloxone is split between broad composition and formulation or method-of-use improvements. Supplier switching risks rise when a buyer needs to change dosage form, manufacturing method, or specific formulation details covered by active patents.
Practical supplier switching constraints
- If a product is still under active patents on formulation or manufacturing method, a generic/parallel supplier must confirm “freedom to operate” for the specific dosage and process.
- If a buyer switches from one dosage format to another (tablet to film), formulation patent exposure increases.
What generic entry risks exist that affect supplier availability?
Featured snippet answer: Generic entry risks include patent litigation, regulatory delays, and supply chain qualification bottlenecks at CMOs. For buprenorphine/naloxone, sublingual performance and controlled dosing make CMO capacity planning a key constraint.
Paragraph IV and litigation impact on supply
When suppliers pursue abbreviated approval pathways subject to patent challenges, launch timing can compress or delay, changing available supply.
Which regulators and regulatory filings govern suppliers of buprenorphine/naloxone?
Featured snippet answer: US FDA filings drive supplier qualification for both APIs and finished products, typically via DMFs for APIs and ANDAs or 505(b)(2) filings for finished dosage.
API documentation expectations
- US DMF (Type II for drug substances)
- EU ASMF/CEP alignment where used
- Letter of authorization requirements with controlled disclosure
Finished product documentation expectations
- ANDA references for bioequivalence and equivalency
- Chemistry manufacturing and controls (CMC) congruence
- Labeling, NDC allocation, and distribution compliance
How should buyers structure a supplier qualification plan for buprenorphine/naloxone?
Featured snippet answer: A qualification plan should treat the supply decision as three workstreams: regulatory file validation, technical equivalence testing, and scale-up/manufacturing risk management.
Workstream 1: Regulatory
- Confirm DMF/ASMF status and vendor authorization coverage
- Confirm CMO capability aligns with intended ANDA/505(b)(2) CMC package
Workstream 2: Technical
- API characterization matching target specs
- Finished dose performance verification (dissolution, disintegration, uniformity)
- Stability protocol acceptance and trend review
Workstream 3: Manufacturing and supply continuity
- Capacity commitments for seasonal/initiative demand spikes
- Change control maturity (process and supplier changes)
- Batch release and deviation handling capacity
Key takeaways
- Supplier availability for buprenorphine hydrochloride and naloxone hydrochloride is bifurcated between API producers and CMOs producing sublingual combination dosage forms.
- Selection for APIs centers on regulatory file readiness (US DMF/ASMF) and impurity and salt-form control; selection for finished products centers on sublingual performance and validated CMC packages.
- Patent and litigation dynamics can constrain which formulations and processes suppliers can use, affecting sourcing timelines.
- Buyers should qualify suppliers through a three-part plan: regulatory file validation, technical equivalence, and manufacturing continuity.
FAQs
Which vendors are approved for buprenorphine/naloxone combination film manufacturing?
Finished product vendors typically operate through marketing authorization holders and manufacturers of record; film-specific qualification depends on the exact ANDA and manufacturing site rather than a universal vendor list.
Can I source buprenorphine hydrochloride and naloxone hydrochloride from different API suppliers for one finished product?
Yes in principle, but this raises change-control and regulatory comparability issues tied to impurity profiles and the finished-dose formulation process.
What documentation is required to qualify an API supplier for buprenorphine hydrochloride or naloxone hydrochloride?
Typically a US DMF or EU ASMF/CEP package plus impurity and characterization reports aligned to the planned finished-dose specs.
Do tablet and film versions use the same CMO supply chain?
Some CMO infrastructure overlaps, but film and tablet manufacturing typically require different process validation, equipment setups, and stability protocols.
How does shortage risk appear for buprenorphine/naloxone supply?
Shortages show up through capacity constraints at CMOs and launch timing shifts caused by litigation or regulatory events affecting specific NDCs.
References
No sources were provided in the prompt.
